Type 1 Diabetes
Conditions
Interventions
Latent Autoimmune Diabetes in Adults Group 1:Lactobacillus rhamnosus Probio-M9
Latent Autoimmune Diabetes in Adults Group 2:probiotics
Other immune-mediated diabetes Group 1:Lactobacillus rhamnosus Probio-M9
Other immune-mediated diabetes Group 2:probiotics
Idiopathic type 1 diabetes Group 1: Lactobacillus rhamnosus Probio-M9
Idiopathic type 1 diabetes Group 2:probiotics
Sponsors
Weihai Municipal Hospital
Eligibility
Sex/Gender
All
Age
16 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. The diagnosis and classification of type 1 diabetes met the clinical diagnosis and classification criteria of American Diabetes Association, which was divided into immune-mediated diabetes (including adult delayed autoimmune diabetes) and idiopathic type 1 diabetes. The study was divided into 3 groups:1.Latent Autoimmune Diabetes in Adults(age >30 years at diagnosis, positive diabetes-related autoantibodies, such as glutamate decarboxylase antibody, and no insulin treatment for at least 6 months after diagnosis); 2.Other immune-mediated diabetes (positive for diabetes-related autoantibodies, such as glutamate decarboxylase antibody);3. Idiopathic type 1 diabetes (permanent insulin reduction, such as C-peptide = 16 years. 3. Agree to participate in this study and sign informed consent. The patient was conscious and able to complete the examination, questionnaire survey and medical history collection by himself or with the help of his family.
Exclusion criteria
Exclusion criteria: 1. Have severe cognitive impairment that affects written and verbal expression; 2. Patients with severe aphasia or dysarthria; 3. Neurological and psychiatric diseases (degenerative and/or vascular dementia, Parkinson's disease, stroke and major depression), severe multiple organ diseases (anemia, lung disease, cancer) and other cognitive diseases; 4. Other serious physical diseases or serious abnormalities of thyroid, liver and kidney function; 5. Patients who needed to take immunosuppressants for a long time or took antibiotics within 1 month before enrollment and during follow-up; 6. During the follow-up period, stop taking medication or adjust the sample at will; 7. During the follow-up period, patients also took defecation promoting drugs, such as polyethylene glycol electrolyte, phenolphthalein tablets, senna leaf, etc. 8. Patients with chronic digestive diseases or tumors, such as gastrointestinal ulcer, inflammatory enteritis, severe liver disease, etc. 9. People who are allergic to the tested samples or show obvious gastrointestinal symptoms, such as being unable to tolerate them.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| cognitive;Depression;Anxiety; | — |
Countries
China
Contacts
Public ContactJinbiao Zhang
Weihai Municipal Hospital
Outcome results
None listed